<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(3)</volume><submitter>Porro B</submitter><pubmed_abstract>Clinical data indicate that low circulating l-homoarginine (HArg) concentrations are associated with cardiovascular (CV) disease, CV mortality, and all-cause mortality. A high number of LC-based analytical methods for the quantification of HArg, in combination with the l-arginine (Arg)-related pathway metabolites, have been reported. However, these methods usually consider a limited panel of analytes. Thus, in order to achieve a comprehensive picture of the Arg metabolism, we described an improved targeted metabolomic approach based on a multiple reaction monitoring (MRM) mass spectrometry method for the simultaneous quantification of the Arg/nitric oxide (NO) pathway metabolites. This methodology was then employed to quantify the plasma concentrations of these analytes in a cohort of indi</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>1136</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8835333</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>An Optimized MRM-Based Workflow of the l-Arginine/Nitric Oxide Pathway Metabolites Revealed Disease- and Sex-Related Differences in the Cardiovascular Field.</pubmed_title><pmcid>PMC8835333</pmcid><pubmed_authors>Cosentino N</pubmed_authors><pubmed_authors>Conte E</pubmed_authors><pubmed_authors>Cavalca V</pubmed_authors><pubmed_authors>Capra N</pubmed_authors><pubmed_authors>Porro B</pubmed_authors><pubmed_authors>Banfi C</pubmed_authors><pubmed_authors>Eligini S</pubmed_authors></additional><is_claimable>false</is_claimable><name>An Optimized MRM-Based Workflow of the l-Arginine/Nitric Oxide Pathway Metabolites Revealed Disease- and Sex-Related Differences in the Cardiovascular Field.</name><description>Clinical data indicate that low circulating l-homoarginine (HArg) concentrations are associated with cardiovascular (CV) disease, CV mortality, and all-cause mortality. A high number of LC-based analytical methods for the quantification of HArg, in combination with the l-arginine (Arg)-related pathway metabolites, have been reported. However, these methods usually consider a limited panel of analytes. Thus, in order to achieve a comprehensive picture of the Arg metabolism, we described an improved targeted metabolomic approach based on a multiple reaction monitoring (MRM) mass spectrometry method for the simultaneous quantification of the Arg/nitric oxide (NO) pathway metabolites. This methodology was then employed to quantify the plasma concentrations of these analytes in a cohort of indi</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-05-29T21:04:19.582Z</modification><creation>2025-05-29T21:04:19.582Z</creation></dates><accession>S-EPMC8835333</accession><cross_references><pubmed>35163055</pubmed><doi>10.3390/ijms23031136</doi></cross_references></HashMap>